4.5 Interaction with other medicinal products and other forms of interaction  
 No formal assessments of pharmacokinetic interactions between arsenic trioxide and other therapeutic medicinal products have been cond ucted.  
 Medicinal products known to cause QT/QTc interval prolongation, hypokal aemia or hypomagnesaemia 
 QT/QTc prolongation is expected during treatment with arsenic trioxide, and Torsade  de pointes and complete heart block have been reported. Patients who are receiving, or who have received, medicinal 7 
 products known to cause hypokal aemia or hypomagnesaemia, such as diuretics or amphotericin B, may be at higher risk for torsade de pointes. Caution is adv ised when arsenic trioxide is co -administered with other medicinal products known to cause QT/QTc interval prolongation such as macrolide antibiotics, the antipsychotic thioridazine, or medicinal products known to cause hypokal aemia or hypomagnesaemia. Add itional information about QT prolonging medicinal agents is provided in Section 4.4.  
 Medicinal products known to cause hepatotoxic effects  
 Hepatotoxic effects may occur during the treatment with arsenic trioxide, caution is advised when arsenic trioxide is co-administered with other medicinal products known to cause hepatotoxic effects (see section 4.4 and 4.8).  
 Other antileukaemic medicinal products  
 The influence of arsenic trioxide on the efficacy of other antileukaemic medicinal products is unknown. 
 
